Several clinical trials are ongoing, with encouraging results for sjögren’s syndrome (SS) and systemic sclerosis (SSc), reinforcing BAFF-targeting therapies as a potential strategy for autoimmune diseases treatment. This evidence concerns the gene TNFSF13B and Sjogren syndrome.